tiprankstipranks
Advertisement
Advertisement

CGON Stock Latest News

CG Oncology Maintained at Buy as Strong Phase 3 Cretostimogene Data Support Unchanged $100 Price Target
RatingsCG Oncology Maintained at Buy as Strong Phase 3 Cretostimogene Data Support Unchanged $100 Price Target
4d ago
CGON
CG Oncology announces publication of BOND-003 results in The Lancet Oncology
PremiumThe Fly
CG Oncology announces publication of BOND-003 results in The Lancet Oncology
5d ago
CGON
Big Insider Buying Puts These 2 Stocks on the Radar
PremiumMarket News
Big Insider Buying Puts These 2 Stocks on the Radar
28d ago
ADBE
CGON
CG Oncology 1.15M share Block Trade priced at $66.87
PremiumThe Fly
CG Oncology 1.15M share Block Trade priced at $66.87
1M ago
CGON
Closing Bell Movers: Micron soars 14% after beat and raise
PremiumThe Fly
Closing Bell Movers: Micron soars 14% after beat and raise
1M ago
MU
ARM
CG Oncology 1.15M share Block Trade; price range $66.87-$67.87
PremiumThe FlyCG Oncology 1.15M share Block Trade; price range $66.87-$67.87
1M ago
CGON
CG Oncology Shareholders Back Directors and Governance Proposals
Premium
Company Announcements
CG Oncology Shareholders Back Directors and Governance Proposals
2M ago
8K
CGON
Oncolytics promotes John McAdory to COO
Premium
The Fly
Oncolytics promotes John McAdory to COO
2M ago
CGON
ONCY
Alec Stranahan Reiterates Buy on CG Oncology, Lifts Price Target to $87 as Commercialization Plans Stay on Track
PremiumRatings
Alec Stranahan Reiterates Buy on CG Oncology, Lifts Price Target to $87 as Commercialization Plans Stay on Track
2M ago
CGON
CG Oncology announces departure of president, COO Ambaw Bellete
PremiumThe Fly
CG Oncology announces departure of president, COO Ambaw Bellete
2M ago
CGON
Wolfe sees CG Oncology COO exit as operational, no impact to key programs
PremiumThe Fly
Wolfe sees CG Oncology COO exit as operational, no impact to key programs
2M ago
CGON
CG Oncology Reshapes Executive Team Amid Leadership Transition
PremiumCompany Announcements
CG Oncology Reshapes Executive Team Amid Leadership Transition
2M ago
8K
CGON
CG Oncology initiated with a Peer Perform at Wolfe Research
PremiumThe FlyCG Oncology initiated with a Peer Perform at Wolfe Research
2M ago
CGON
Buy Rating Reiterated on Robust Cretostimogene Data and De-Risked Phase 2 Program; $100 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on Robust Cretostimogene Data and De-Risked Phase 2 Program; $100 Price Target Maintained
3M ago
CGON
CG Oncology reports first results from CORE-008 Cohort CX
Premium
The Fly
CG Oncology reports first results from CORE-008 Cohort CX
3M ago
CGON
CG Oncology price target raised to $82 from $77 at Truist
PremiumThe Fly
CG Oncology price target raised to $82 from $77 at Truist
3M ago
CGON
CG Oncology price target raised to $81 from $79 at RBC Capital
PremiumThe Fly
CG Oncology price target raised to $81 from $79 at RBC Capital
3M ago
CGON
CG Oncology price target raised to $80 from $77 at Wedbush
PremiumThe Fly
CG Oncology price target raised to $80 from $77 at Wedbush
3M ago
CGON
CG Oncology price target raised to $96 from $91 at JPMorgan
PremiumThe Fly
CG Oncology price target raised to $96 from $91 at JPMorgan
3M ago
CGON
CG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto
PremiumRatingsCG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto
3M ago
CGON
CG Oncology price target lowered to $83 from $84 at BofA
Premium
The Fly
CG Oncology price target lowered to $83 from $84 at BofA
3M ago
CGON
Analyst Reiterates Buy on CG Oncology, Maintains $90 Price Target Ahead of Key Cretostimogene Data Readouts
Premium
Ratings
Analyst Reiterates Buy on CG Oncology, Maintains $90 Price Target Ahead of Key Cretostimogene Data Readouts
3M ago
CGON

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >